Transgene Biotek (TRABI) | Stock Overview & Key Data
Transgene Biotek Performance Comparison
Stock Range
Today's Range
Low: ₹3.95
High: ₹4.45
on September 18, 2025
52 Week Range
Low: ₹3.22
High: ₹7.71
on April 1, 2025
on December 30, 2024
All-Time High: ₹322.50 on January 23, 2006
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR335.4M
EPS
-0.18
P/E Ratio (TTM)
-48.67
Forward P/E
N/A
P/B Ratio
3.04
PEG Ratio
0.16
Div. Yield
N/A
ROE
-6.74%
Beta
0.803
Debt to Equity
144.77
Financial Highlights
Profitability
Gross Margin
100.00%
Operating Margin
-380.20%
Profit Margin
100.00%
Returns and Earnings
Return on Assets (TTM)
-0.47%
Return on Equity (TTM)
-6.74%
EBITDA
INR-8.8M
Net Income (TTM)
INR-13.1M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR0.03
Quarterly Revenue Growth (YoY)
0.40%
Quarterly Earnings Growth (YoY)
0.61%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Transgene Biotek TRABI | 335.38M Small-cap | 14.66% | -1.13% | 1.86% | 14.06% | -28.78% | -43.99% | 36.45% | -0.45% |
| Biocon BIOCON | 480.91B Large-cap | -2.70% | -2.73% | 0.48% | 6.33% | -3.92% | -3.01% | 24.86% | -17.21% |
| OneSource Specialty ONESOURCE | 211.08B Large-cap | -0.35% | 0.29% | -15.42% | 25.01% | 7.34% | 7.34% | 7.34% | 7.34% |
| Dishman Carbogen DCAL | 41.96B Small-cap | 2.36% | 5.70% | 6.73% | 31.21% | -2.51% | 45.41% | 185.57% | 82.33% |
| Zota Health Care ZOTA | 40.90B Small-cap | -2.82% | 7.26% | 53.28% | 88.37% | 82.85% | 120.72% | 361.23% | 898.97% |
| Panacea Biotec PANACEABIO | 26.67B Small-cap | 7.79% | 12.52% | 5.04% | 17.28% | 4.53% | 46.26% | 236.43% | 135.83% |
Ownership & Short Interest
Insider Ownership
21.68%
Institutional Ownership
0.00%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
96K
Average 90-Day Volume
53K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is TRABI's 52-week high and low?
- In the last 52 weeks, Transgene Biotek reached a high of ₹7.71 (on December 30, 2024) and a low of ₹3.22 (on April 1, 2025).
- What is the market cap and P/E ratio for TRABI?
- Curious about Transgene Biotek's size and valuation? Its market capitalization stands at 335.38M. When it comes to valuation, the P/E ratio (trailing twelve months) is -48.67, and the forward P/E (looking ahead) is N/A.
- Does TRABI pay dividends? If so, what's the yield?
- As for dividends, Transgene Biotek isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Transgene Biotek's main competitors or similar companies to consider before investing?
When looking at Transgene Biotek, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Biocon
BIOCON480.91B Healthcare Biotechnology -3.01% 24.86% OneSource Specialty
ONESOURCE211.08B Healthcare Biotechnology 7.34% 7.34% Dishman Carbogen
DCAL41.96B Healthcare Biotechnology 45.41% 185.57% Zota Health Care
ZOTA40.90B Healthcare Biotechnology 120.72% 361.23% Panacea Biotec
PANACEABIO26.67B Healthcare Biotechnology 46.26% 236.43% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Transgene Biotek Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Transgene Biotek's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -6.74%, the Debt to Equity ratio from the most recent quarter is 144.77, and its Gross Profit Margin stands at 100.00%.
- What is the recent revenue and earnings growth for TRABI?
- Looking at Transgene Biotek's growth, its revenue over the trailing twelve months (TTM) was INR3M. Compared to the same quarter last year (YoY), quarterly revenue grew by 0.40%, and quarterly earnings saw a YoY growth of 0.61%.
- How much of TRABI stock is held by insiders and institutions?
- Wondering who owns Transgene Biotek stock? Company insiders (like executives and directors) hold about 21.68% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.